EPHA2 and pancreatic neoplasm: More recently, the auristatin-based hSD5-vedotin antibody–drug conjugate targeting EphA2 was tested in a preclinical setting [96], and in pancreatic cancer, hSD5-vedotin triggered EphA2 endocytosis, strongly inhibited in vitro tumor growth and promoted apoptosis as well as suppressed tumor growth in pancreatic cancer xenograft animal models [96].